Alzheimer’s vaccine research has progressed significantly since the disease was first identified over a hundred years ago, with treatments now available that can reduce harmful proteins in the brain associated with the condition. Vaccine trials are currently underway to eliminate these proteins, with one of the most promising candidates being UB-311 developed by American company Vaxxinity. The synthetic, peptide-based immunotherapy has proved safe and tolerable in phase 2 trials and Japanese healthcare company Eisai recently developed LEQEMBI, a cost-effective vaccine for the disease.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
